Pre-Approval Access for Administration of Daratumumab Subcutaneously (SC) in Participants Who Are Unable to Receive Intravenous (IV) Daratumumab

Janssen (J&J Innovative Medicine)

Status

Treatments: Drug: Daratumumab

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT04264884

CR108780

54767414MMY4031 (Other Identifier)

Details and patient eligibility

About

The purpose of this pre-approval access (PAA) program is to provide treatment to participants with serious/life-threatening diseases or conditions.

Sex

Volunteers: No Healthy Volunteers

Inclusion criteria

Exclusion criteria